Malaria vaccine trial targets kids with HIV
NCT ID NCT05385510
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the safety and immune response of the R21/Matrix-M malaria vaccine in 122 African children aged 5-36 months, some living with HIV and some without. The goal was to see if the vaccine is safe and produces an immune response in these children. The trial has been completed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MRC/UVRI & LSHTM Uganda Research Unit
Entebbe, Uganda
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new strategy break the cycle of HIV care dropout?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a pill make your blood deadly to malaria mosquitoes?
- Can a new vaccine stop malaria in its tracks?
- Can a new malaria vaccine slash childhood cases? a massive real-world test seeks answers.
- One shot, six months of malaria shield? a new trial tests a powerful antibody in children